hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
Abstract
:1. Introduction
2. Results
2.1. Evaluation of the hENT1 SP120 Antibody Predictive Value
2.2. Evaluation of Additional hENT1 Antibodies Predictive Value
2.3. Evaluation of hENT1 mRNA Predictive Value
2.4. Evaluation of hENT1 Expression in Metastasis and Correlation with the Primary Tumor
3. Discussion
4. Material and Methods
4.1. Patients
4.2. Immunohistochemistry
4.3. Western Blot Analyses
4.4. mRNA Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Bird, N.T.E.; Elmasry, M.; Jones, R.; Psarelli, E.; Dodd, J.; Malik, H.; Greenhalf, W.; Kitteringham, N.; Ghaneh, P.; Neoptolemos, J.P.; et al. Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. Br. J. Surg. 2017, 104, 328–336. [Google Scholar] [CrossRef] [PubMed]
- Liu, Z.-Q.; Han, Y.-C.; Zhang, X.; Chu, L.; Fang, J.-M.; Zhao, H.-X.; Chen, Y.-J.; Xu, Q. Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis. PLoS ONE 2014, 9, e87103. [Google Scholar] [CrossRef] [PubMed]
- Maréchal, R.; Bachet, J.-B.; Mackey, J.R.; Dalban, C.; Demetter, P.; Graham, K.; Couvelard, A.; Svrcek, M.; Bardier-Dupas, A.; Hammel, P.; et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012, 143, 664–674.e16. [Google Scholar] [CrossRef] [PubMed]
- Greenhalf, W.; Ghaneh, P.; Neoptolemos, J.P.; Palmer, D.H.; Cox, T.F.; Lamb, R.F.; Garner, E.; Campbell, F.; Mackey, J.R.; Costello, E.; et al. Pancreatic Cancer hENT1 Expression and Survival from Gemcitabine in Patients from the ESPAC-3 Trial. J. Natl. Cancer Inst. 2013, 106, djt347. [Google Scholar] [CrossRef] [PubMed]
- Farrell, J.J.; Elsaleh, H.; Garcia, M.; Lai, R.; Ammar, A.; Regine, W.F.; Abrams, R.; Benson, A.B.; Macdonald, J.; Cass, C.E.; et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009, 136, 187–195. [Google Scholar] [CrossRef] [PubMed]
- Sinn, M.; Riess, H.; Sinn, B.V.; Stieler, J.M.; Pelzer, U.; Striefler, J.K.; Oettle, H.; Bahra, M.; Denkert, C.; Bläker, H.; et al. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. Eur. J. Cancer 2015, 51, 1546–1554. [Google Scholar] [CrossRef] [PubMed]
- Poplin, E.; Wasan, H.; Rolfe, L.; Raponi, M.; Ikdahl, T.; Bondarenko, I.; Davidenko, I.; Bondar, V.; Garin, A.; Boeck, S.; et al. Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. J. Clin. Oncol. 2013, 31, 4453–4461. [Google Scholar] [CrossRef] [PubMed]
- Ormanns, S.; Heinemann, V.; Raponi, M.; Isaacson, J.; Laubender, R.P.; Haas, M.; Kruger, S.; Kleespies, A.; Mann, E.; Bartosiewicz, M.; et al. Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. Eur. J. Cancer 2014, 50, 1891–1899. [Google Scholar] [CrossRef] [PubMed]
- Svrcek, M.; Cros, J.; Maréchal, R.; Bachet, J.-B.; Fléjou, J.-F.; Demetter, P. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: A comparison between murine and rabbit antibodies. Histopathology 2015, 66, 457–462. [Google Scholar] [CrossRef] [PubMed]
- Kalloger, S.E.; Riazy, M.; Tessier-Cloutier, B.; Karasinska, J.M.; Gao, D.; Peixoto, R.D.; Samimi, S.; Chow, C.; Wong, H.-L.; Mackey, J.R.; et al. A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. J Pathol. Clin. Res. 2017, 3, 179–190. [Google Scholar] [CrossRef] [PubMed]
- Nakagawa, N.; Murakami, Y.; Uemura, K.; Sudo, T.; Hashimoto, Y.; Kondo, N.; Sueda, T. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 2013, 153, 565–575. [Google Scholar] [PubMed]
- Morinaga, S.; Nakamura, Y.; Watanabe, T.; Mikayama, H.; Tamagawa, H.; Yamamoto, N.; Shiozawa, M.; Akaike, M.; Ohkawa, S.; Kameda, Y.; et al. Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy. Ann. Surg. Oncol. 2011, 19 (Suppl. 3), S558–S564. [Google Scholar] [CrossRef] [PubMed]
- Sierzega, M.; Pach, R.; Kulig, P.; Legutko, J.; Kulig, J. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients with Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy. Pancreas 2017, 46, 684–689. [Google Scholar] [CrossRef] [PubMed]
- Eto, K.; Kawakami, H.; Kuwatani, M.; Kudo, T.; Abe, Y.; Kawahata, S.; Takasawa, A.; Fukuoka, M.; Matsuno, Y.; Asaka, M.; et al. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer. Br. J. Cancer 2013, 108, 1488–1494. [Google Scholar] [CrossRef] [PubMed]
- Bachet, J.-B.; Hammel, P.; Desramé, J.; Meurisse, A.; Chibaudel, B.; André, T.; Debourdeau, P.; Dauba, J.; Lecomte, T.; Seitz, J.-F.; et al. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): A non-comparative, multicentre, open-label, randomised phase 2 trial. Lancet Gastroenterol. Hepatol. 2017, 2, 337–346. [Google Scholar] [CrossRef]
- Rajabpour, A.; Afgar, A.; Mahmoodzadeh, H.; Radfar, J.-E.-D.; Rajaei, F.; Teimoori-Toolabi, L. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells. Cancer Chemother. Pharmacol. 2017, 80, 765–775. [Google Scholar] [CrossRef] [PubMed]
- Weizman, N.; Krelin, Y.; Shabtay-Orbach, A.; Amit, M.; Binenbaum, Y.; Wong, R.J.; Gil, Z. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene 2013, 33, 3812–3819. [Google Scholar] [CrossRef] [PubMed]
- Hessmann, E.; Patzak, M.S.; Klein, L.; Chen, N.; Kari, V.; Ramu, I.; Bapiro, T.E.; Frese, K.K.; Gopinathan, A.; Richards, F.M.; et al. Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer. Gut 2017, 67, 497–507. [Google Scholar] [CrossRef] [PubMed]
- Tiriac, H.; Belleau, P.; Engle, D.D.; Plenker, D.; Deschênes, A.; Somerville, T.; Froeling, F.E.M.; Burkhart, R.A.; Denroche, R.E.; Jang, G.-H.; et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018, 8, 1112–1129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Type of Couples | Concordance Between Primary Tumor and Metastases (0–1 vs. 2) |
---|---|
All couples | 45/54: 83% |
Synchronous (n = 32) | 30/32: 94% |
FNA (n = 17) | 16/17: 94% |
Autopsy (n = 5) | 4/5: 80% |
Metachronous (n = 22) | 15/22: 68% |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Raffenne, J.; Nicolle, R.; Puleo, F.; Le Corre, D.; Boyez, C.; Marechal, R.; Emile, J.F.; Demetter, P.; Bardier, A.; Laurent-Puig, P.; et al. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Cancers 2019, 11, 1808. https://doi.org/10.3390/cancers11111808
Raffenne J, Nicolle R, Puleo F, Le Corre D, Boyez C, Marechal R, Emile JF, Demetter P, Bardier A, Laurent-Puig P, et al. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Cancers. 2019; 11(11):1808. https://doi.org/10.3390/cancers11111808
Chicago/Turabian StyleRaffenne, Jerome, Remy Nicolle, Francesco Puleo, Delphine Le Corre, Camille Boyez, Raphael Marechal, Jean François Emile, Peter Demetter, Armelle Bardier, Pierre Laurent-Puig, and et al. 2019. "hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status" Cancers 11, no. 11: 1808. https://doi.org/10.3390/cancers11111808